Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medrx CoTSE:4586 62 EV-to-EBITDA is -6.11 as of Aug. 29, 2026. GuruFocus rates TSE:4586 with a GF Score™ of 62/100 and a GF Value™ of 円70.60 (Fairly Valued). The stock has 3 warning signs investors should review. Among 733 Drug Manufacturers companies, Medrx Co ranks worse than 136425.51% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Medrx Co's enterprise value is 円3,292.59 Mil.
Medrx Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was 円-538.98 Mil. Therefore, Medrx Co's EV-to-EBITDA for today is -6.11.
The historical rank and industry rank for Medrx Co's EV-to-EBITDA or its related term are showing as below:
TSE:4586'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.13 Med: -3.09 Max: -0.46
Current: -6.11
During the past 13 years, the highest EV-to-EBITDA of Medrx Co was -0.46. The lowest was -16.13. And the median was -3.09.
TSE:4586's EV-to-EBITDA is ranked worse than 100% of 733
companies
in the Drug Manufacturers industry
Industry Median: 13.06
vs TSE:4586: -6.11
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medrx Co's share price for today is 円67.00.
Medrx Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-9.270.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Medrx Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medrx Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medrx Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medrx Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medrx Co's EV-to-EBITDA falls into.
Medrx Co's current Enterprise Value is 円3,292.59 Mil.
Medrx Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-538.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medrx Co (TSE:4586) has a EV-to-EBITDA of -6.11 as of Aug. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medrx Co. According to the industry distribution chart, Medrx Co ranks #999999 out of 733 companies in the Drug Manufacturers industry.
Is Medrx Co's EV-to-EBITDA too high?
Medrx Co's current EV-to-EBITDA is -6.11. Based on the distribution chart, Medrx Co ranks #999999 out of 733 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medrx Co has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medrx Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medrx Co ranks #999999 out of 733 companies for EV-to-EBITDA. This places Medrx Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.06, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medrx Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medrx Co's current EV-to-EBITDA is -6.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medrx Co stock overvalued right now?
Based on GuruFocus' analysis, Medrx Co (TSE:4586) is currently considered Fairly Valued. The stock's GF Value™ is 円70.60, compared to a current price of 円67.00 — trading 5.1% below its estimated fair value. The current EV-to-EBITDA is -6.11. Medrx Co's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Medrx Co (TSE:4586), the current EV-to-EBITDA is -6.11 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medrx Co (TSE:4586) Overvalued in 2026?
Based on GuruFocus' analysis, Medrx Co stock appears to be undervalued.
The current stock price of 円67.00 is trading 5.1% below its estimated GF Value™ of 円70.60.
GuruFocus considers Medrx Co to be Fairly Valued.
Key valuation signals for TSE:4586:
EV-to-EBITDA: -6.11
GF Value™: 円70.60 vs. price of 円67.00 (5.1% below fair value)
No single metric tells the full story. See the TSE:4586 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medrx Co Ltd is a pharmaceutical drug development company founded in January, 2002. The Company engaged in the research and development of pharmaceutical products utilizing the pharmaceutical formulation technology based on ionic liquid transdermal system. The Company develops new pharmaceutical candidates and licenses other companies to produce the pharmaceuticals after clinical trials. Its main products include analgesic patches for anti-inflammatory and pain relief.
62GF Score
Get the complete analysis for TSE:4586
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4586 has been successfully added to your 
